Inclusion Criteria:

- Patients must have histologically or cytologically confirmed inoperable or metastatic
adenocarcinoma of the stomach or lower third of the oesophagus refractory or
intolerable to standard therapy.

- Patients must have measurable or evaluable disease.

- Age >= 201years

- ECOG performance status of 0 to 2

- Life expectancy at least 3 months

- Patients must have normal organ and marrow function as defined below:

- absolute neutrophil count >=1,500/mcL

- platelets >=100,000/mcL

- total bilirubin within normal institutional limits

- AST(SGOT)/ALT(SGPT) <=2.5 X institutional upper limit of

- Normal creatinine within normal institutional limits

- Patients must be HLA-A*2402

- Patients must have recover from all reversible treatment toxicity from prior
chemotherapy, radiotherapy or surgery.

- The effects of OTSGC-A24 on the developing human fetus at the recommended therapeutic
dose are unknown. For this reason, women of child-bearing potential and men must
agree to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation. Should
a woman become pregnant or suspect she is pregnant while participating in this study,
she should inform her treating physician immediately.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- Patients receiving any other investigational agents.

- History of significant gastrointestinal bleeding that required intervention within
the prior 1 month is ineligible; inherited bleeding diathesis or coagulopathy.

- Serious non healing wound and peptic ulcer disease

- Previous history of intestinal perforation

- Invasive procedures defined as follows (Insertion of a vascular access device is not
considered major/minor surgery):

- Major surgical procedure, open biopsy or significant traumatic injury =28 days prior
to -registration

- Anticipation of need for major surgical procedures during the course of the study

- Core biopsy <=7 days

- Minor surgery <=2 weeks

- Symptomatic CNS metastasis

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg),
symptomatic congestive heart failure, unstable angina pectoris, myocardial
infarction/cerebrovascular event (<=6 months prior to study entry), cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements, long term systemic immunosuppressant or corticosteroid.

- Women who are breast-feeding or pregnant are excluded from this study